These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 26615894)

  • 1. Effects of Paroxetine,a CYP2D6 Inhibitor, on the Pharmacokinetic Properties of Hydrocodone After Coadministration With a Single-entity,Once-daily, Extended-release HydrocodoneTablet.
    Kapil RP; Friedman K; Cipriano A; Michels G; Shet M; Mondal S; Harris SC
    Clin Ther; 2016 Jan; 38(1):228-9. PubMed ID: 26615894
    [No Abstract]   [Full Text] [Related]  

  • 2. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
    Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
    Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacokinetic evaluation of single and multiple doses of extended-release hydrocodone bitartrate in subjects experiencing surgical or osteoarthritic pain.
    Robinson CY; Rubino CM; Farr SJ
    J Opioid Manag; 2015; 11(5):405-15. PubMed ID: 26535968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers.
    Ruiz-Garcia A; Giri N; LaBadie RR; Ni G; Boutros T; Richie N; Kocinsky HS; Checchio TM; Bello CL
    J Clin Pharmacol; 2014 May; 54(5):555-62. PubMed ID: 24293056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine.
    Mikami A; Ohtani H; Hori S; Sawada Y
    Int J Clin Pharmacol Ther; 2013 May; 51(5):374-82. PubMed ID: 23357843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
    Darwish M; Yang R; Tracewell W; Robertson P; Bond M
    Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets.
    Berwaerts J; Cleton A; Herben V; van de Vliet I; Chang I; van Hoek P; Eerdekens M
    Pharmacopsychiatry; 2009 Jul; 42(4):158-63. PubMed ID: 19585395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
    Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude.
    Venkatakrishnan K; Obach RS
    Drug Metab Dispos; 2005 Jun; 33(6):845-52. PubMed ID: 15788540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-release hydrocodone (Hysingla ER) for pain.
    Med Lett Drugs Ther; 2015 May; 57(1468):71-2. PubMed ID: 25941956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions.
    Madadi P; Hildebrandt D; Gong IY; Schwarz UI; Ciszkowski C; Ross CJ; Sistonen J; Carleton BC; Hayden MR; Lauwers AE; Koren G
    Pediatrics; 2010 Oct; 126(4):e986-9. PubMed ID: 20837591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
    Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G
    Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-entity hydrocodone extended-release capsules in opioid-tolerant subjects with moderate-to-severe chronic low back pain: a randomized double-blind, placebo-controlled study.
    Rauck RL; Nalamachu S; Wild JE; Walker GS; Robinson CY; Davis CS; Farr SJ
    Pain Med; 2014 Jun; 15(6):975-85. PubMed ID: 24517082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers.
    Glue P; Winter H; Garbe K; Jakobi H; Lyudin A; Lenagh-Glue Z; Hung CT
    J Clin Pharmacol; 2015 Jun; 55(6):680-7. PubMed ID: 25651476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paroxetine markedly increases plasma concentrations of ophthalmic timolol; CYP2D6 inhibitors may increase the risk of cardiovascular adverse effects of 0.5% timolol eye drops.
    Mäenpää J; Volotinen-Maja M; Kautiainen H; Neuvonen M; Niemi M; Neuvonen PJ; Backman JT
    Drug Metab Dispos; 2014 Dec; 42(12):2068-76. PubMed ID: 25261563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydrocodone in postoperative personalized pain management: pro-drug or drug?
    Stauble ME; Moore AW; Langman LJ; Boswell MV; Baumgartner R; McGee S; Metry J; Jortani SA
    Clin Chim Acta; 2014 Feb; 429():26-9. PubMed ID: 24269714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Paroxetine: pharmacokinetics and pharmacodynamics].
    Hiemke C
    Fortschr Neurol Psychiatr; 1994 Sep; 62 Suppl 1():2-8. PubMed ID: 7959522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamics and persistence of CYP2D6 inhibition by paroxetine.
    Juřica J; Žourková A
    J Clin Pharm Ther; 2013 Aug; 38(4):294-300. PubMed ID: 23437966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 12-Month safety and effectiveness of once-daily hydrocodone tablets formulated with abuse-deterrent properties in patients with moderate to severe chronic pain.
    Wen W; Taber L; Lynch SY; He E; Ripa S
    J Opioid Manag; 2015; 11(4):339-56. PubMed ID: 26312961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain.
    Wen W; Sitar S; Lynch SY; He E; Ripa SR
    Expert Opin Pharmacother; 2015; 16(11):1593-606. PubMed ID: 26111544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.